Piper Sandler Maintains Neutral on Vertex Pharmaceuticals, Lowers Price Target to $242
Piper Sandler analyst Do Kim maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Neutral and lowers the price target from $249 to $242.
Vertex Pharmaceuticals Q1 EPS $3.52 Beats $3.49 Estimate, Sales $2.10B Beat $2.08B Estimate
Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $3.52 per share which beat the analyst consensus estimate of $3.49 by 0.86 percent. This is a 18.12 percent increase over earnings of $2.98 per share
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Analyst Ratings for Vertex Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 6.39% on an annualized basis producing an average annual return of 17.51%. Currently, Vertex Pharmaceuticals has a market capitalization of $65.74 billion.
Vertex Pharma’s Stem Cell Derived Diabetes Treatment Trial Put On Hold
The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) VX-880 Phase 1/2 study due to a determination that there…
Vertex Pharma Reports Health Canada Granted Marketing Authorization For Its TRIKAFTA In Children With Cystic Fibrosis Ages 6-11
-Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®-
-Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals
If You Invested $1000 In Vertex Pharmaceuticals 15 Years Ago, Here’s How Much You Would Have Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.29% on an annualized basis producing an average annual return of 15.84%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.91 billion.
Twitter And 4 Other Stocks Insiders Are Selling
Although gold futures traded higher on Monday, there were a few notable insider trades.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.